Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

about

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

Item

http://www.wikidata.org/entity/Q43540210

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

@en

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

@nl

type

Item

label

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

@en

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

@nl

prefLabel

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

@en

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

@nl

P1476

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

@en

P2093

Margaret K Yu

http://www.w3.org/2001/XMLSchema#string

Sun H Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

National trends in treatment of type 2 diabetes mellitus, 1994-2007

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Associations between depressive symptoms and incident ESRD in a diabetic cohort.

Invited commentary: propensity scores.

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.

P304

2104-2106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2215/CJN.10361016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27827307

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5142075

http://www.w3.org/2001/XMLSchema#string